2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 260-262
Access, Representation, Population Health, Treatment Considerations, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Young Adult
PAPER

459 Prospective, longitudinal geriatric assessment and management study in CD19 CAR T-cell therapy for older adults with relapsed or refractory B-cell non-Hodgkin's lymphoma

Min Jung Koh, MD, Soo Jung Kim, PhD, NP2, Maria Bromberg, MS3, Danielle Lutrario, RN, BS4, Danielle Engstler, BS5, Stacy Fernstedt, BS6, Daniel Cameron, BS7, Allison Parascondola8, Amethyst Saldia9, Roni Shouval Jr, MD, PhD10, Silvia Escribano Serrat, MD11, Maria Lia Palomba, MD12, Parastoo B. Dahi, MD13, Gunjan L. Shah, MD, MS14, Michael Scordo, MD15, Miguel-Angel Perales, MD16, Craig Sauter, MD17, Alexander P. Boardman, MD18, Gilles Salles I, MD, PhD19, Jennifer Kimberly Lue, M.D.20, Lorenzo Falchi, MD21, Jae H Park, MD22, Beatriz Korc, MD, PhD23, Arimn Shahrokni, MD24, Sergio Giralt, MD25, Sarah Samorodnitsky, PhD26, Paul Hamlin, MD27, Richard J. Lin, MD, PhD28
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York, New York, United States
24 Memorial Sloan Kettering Cancer Center, New York, New York, United States
25 Memorial Sloan Kettering Cancer Center, New York, New York, United States
26 Memorial Sloan Kettering Cancer Center, New York, New York, United States
27 Memorial Sloan Kettering Cancer Center, New York, New York, United States
28 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Introduction: 

CD19 chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for relapse/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL) and even extended this curative approach to many older adults. However, improving survival, reducing treatment-related mortality, and expanding access among older patients remain unmet needs. We previously showed in a pilot study that longitudinal geriatric assessment (GA) is feasible among older patients undergoing CAR T-cell therapy. We now report the primary analysis of a larger study of GA and GA-guided management in CAR T-cell therapy for older patients.


Methods: We conducted a prospective, single-institution study (NCT04300998) of older patients with R/R B-cell NHL treated with commercial CAR T-cell therapy. Comprehensive GA and GA-guided, supportive care management were conducted by geriatricians prior to and at 3, 6, and 12 months post-infusion. Impairments across GA domains were analyzed as binary variables using standard cutoffs. CAR T-cell therapy was performed according to standard guidelines. Cytokine release syndrome (CRS) and immune effector cell-associated neurologic syndrome (ICANS) were graded using ASTCT criteria. Univariable (UV) and multivariable (MV) Cox proportional hazards models were fitted to assess associations of baseline characteristics and GA impairments with overall survival (OS) and progression-free survival (PFS). UV and MV logistic regression models were fitted to evaluate associations with CRS and ICANS. Domain-specific GA changes from baseline to 12 months were described. 


Results: Ninety-four patients were enrolled. The median age was 73 years (IQR 67-77) and 63% were male. Seventy-two percent of patients had a Karnofsky Performance Status <90 and 16.7% had CAR T-cell Comorbidity Index (CT-CI) score ≥2. Most received Lisocabtagene maraleucel (43%) or Axicabtagene ciloleucel (34%). Pre-infusion GA deficits included impairments in activities of daily living (ADL, 28%), instrumental ADL (IADL, 35%), cognition (22%), and mobility (26%), as well as inadequate social support (34%), limited social activity (78%), distress (51%), and depressive symptoms (47%). GA and GA-guided management was well tolerated with no attributable, high-grade toxicities by CTCAEv5. With a median follow-up of 32 months (IQR 27-36), 2-year OS and PFS were 65% (95% CI:56-76%) and 49% (95% CI:39-60%), respectively. There were 5 NRM events to date; the cumulative incidence of NRM was 2.2% (95% CI 0.41-6.9%) in 1 year and 4.5% (95% CI 1.4-10%) in 2 years. Pre-infusion IADL impairment was associated with inferior OS (hazard ratio [HR]: 2.50, 95% CI 1.30-4.82; p=0.006) and PFS (HR: 2.82, 95% CI 1.61-4.94; p<0.001) in UV analyses. After adjustment for elevated pre-lymphodepletion LDH (MV HR: 5.26, 95% CI 2.54-10.9; p<0.001) and CT-CI score ≥3 (MV HR: 2.61, 95% CI 0.98-6.98; p=0.06), the association with OS was attenuated (MV HR: 1.90, 95% CI 0.96-3.77;  p=0.07). IADL impairment remained independently associated with inferior PFS (MV HR: 2.40, 95% CI 1.30-4.45; p=0.005) after adjustment for pre-lymphodepletion LDH (MV HR:2.82; 95% CI 1.53-5.18; p<0.001) and CT-CI score ≥3 (MV HR: 2.07; 95% CI 0.79-5.42; p=0.1). No GA domain was significantly associated with CRS. Pre-infusion depression was associated with ICANS in UV analysis (p=0.04). Among evaluable patients, IADL impairment decreased from 35.1% at baseline to 19.6% at 12 months, and cognitive impairment decreased from 21.6% to 12.5%. ADL impairment remained stable from baseline, 28%, to 30% at 12 months, whereas mobility impairment showed no consistent trajectory. 


Conclusion: To our knowledge, this is the first prospective study that demonstrates associations of GA domains with survival outcomes among older adults receiving CAR T-cell therapy for R/R B-cell NHL. Moreover, GA-guided management may have contributed to the observed, favorable survival outcomes compared to historical rates, and the meaningful, functional and cognitive recovery post-CAR T-cell therapy. The association between IADL impairment and survival is intriguing and may reflect the underlying physiologic frailty resulting in an unfavorable immune microenvironment that limits CAR T-cell expansion, persistence, or antitumor activity. Longitudinal GA may improve risk stratification and identify modifiable geriatric vulnerabilities for targeted, intensive supportive care interventions during CAR T-cell therapy for older patients.

Min Jung Koh, MD: No relevant conflicts of interest to declare.